about
Present and future challenges in the treatment of haemophilia: the patient's perspectivePresent and future challanges in the treatment of haemophilia: a clinician's perspectiveProduction of factor VIII by human liver sinusoidal endothelial cells transplanted in immunodeficient uPA mice.Direct-to-consumer Marketing to People with HemophiliaThe prevalence of HTLV-1 and its Co-Infection with HCV, HBV and HIV in Hemophilic patientsAdvanced therapies for the treatment of hemophilia: future perspectives.Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivoThe demand for factor VIII and for factor IX and the toll fractionation product surplus management.Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?Clinical and imaging analysis of subclinical hemophilia combined with coxarthrosis: case report and literature review.Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceNovel products for haemostasis.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.Clotting activity of polyphosphate-functionalized silica nanoparticles.Efmoroctocog Alfa: A Review in Haemophilia A.Emerging drugs for the treatment of hemophilia A and B.2017 Clinical trials update: Innovations in hemophilia therapy.High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations.Oral surgery-associated postoperative bleeding in haemophilia patients - a tertiary centre's two decade experience.Recommendations for factor VIII product source to treat patients with haemophilia A.The increased demand for plasma-derived factor VIII in Italy.Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.Treatment for hemophilia: recombinant versus plasma-derived coagulation factors - controversy and debate forever? An ethical medical challenge?Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.Simultaneous bilateral total knee arthroplasty in patients with end-stage hemophilic arthropathy: a mean follow-up of 6 years.A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.Platelet-Targeted Gene Therapy for Hemophilia.
P2860
Q27022801-71019FAF-FAB7-4DB9-89D9-99939EFA00ACQ27026137-27AB2804-FD9E-4B44-B8D1-F2DCD41CDBB5Q35027719-BC4ED092-B41D-44CB-8B1D-C442DBA8896BQ36051468-1AD29C5C-FA82-4E1D-A13E-55D388F5331FQ36270211-87254732-0182-41A4-BD4C-393F43E1AF78Q36552555-ACF7D61E-2B76-41A8-8952-0EA298F08506Q36873312-85CD6518-A34B-4189-A4DB-9FBAD3ABCB60Q36897565-2BED9F72-8CE0-4107-896A-DF66ADE99406Q37370352-04627BF2-0CBC-4AE0-AF9F-FC5CB099ED3BQ37370365-641E07B6-B28B-4806-95CF-E1C372CDCCC0Q37463554-CBD68071-8955-429B-9155-25181C40C7D0Q38054148-4FFE3718-039F-43FF-88A4-08FBA91C3FB6Q38101041-482BF580-363A-4A6E-9D55-334B0E38A421Q38206850-11094D4A-F506-453D-BE42-F3FCE71FEA1BQ38828174-CD4BF733-AE04-401C-BE55-4CFDEEAA8EA7Q38845465-4B381BBD-AFD1-44E9-A2CB-A17950D04FD5Q38917306-65DE9014-D08D-4022-AAB7-34E03D878FC5Q38933707-3DB2BDA9-CA74-48F5-8CAE-F16D8B3C8A3FQ38937725-81EAD9E8-0EA7-460C-A218-EAD322F15605Q40132017-1D948F4C-216A-4238-A16E-9C9C2A7003B6Q41578620-BC86A20B-663D-4436-B8BD-A303C4AFCD22Q41731487-36565A86-6FFC-4CCD-8E95-5B703A3838A7Q42345332-4C4A4BBF-5637-460B-B343-E204665C3128Q42345336-18FFAE95-FA0E-4165-8B17-5C0EE1879CB8Q42958772-D5871981-6414-43A5-9269-CBABAB8E6AF0Q45856894-871C5B98-42B2-45A4-8C37-7BC4EA04FA96Q45859168-6636BD1B-BD9B-4225-9C00-BE952AE4C1F2Q45868343-74BB495E-6E9F-4302-8EA4-97AE4F64EB88Q45869919-7BF27C0B-F30F-4841-80EE-0BB6C1307076Q45886106-32FEE65F-C908-4FC1-9EB4-61F718C39517Q49217209-8B31E623-40F2-4806-88CC-E4347E0D5307Q52744090-A4175F16-1F83-4F87-B17B-1C1D428196A7Q54975244-5EB5A8F0-57B2-46A2-BA08-7B8124BEBBAE
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
How we choose factor VIII to treat hemophilia.
@ast
How we choose factor VIII to treat hemophilia.
@en
How we choose factor VIII to treat hemophilia.
@nl
type
label
How we choose factor VIII to treat hemophilia.
@ast
How we choose factor VIII to treat hemophilia.
@en
How we choose factor VIII to treat hemophilia.
@nl
prefLabel
How we choose factor VIII to treat hemophilia.
@ast
How we choose factor VIII to treat hemophilia.
@en
How we choose factor VIII to treat hemophilia.
@nl
P1433
P1476
How we choose factor VIII to treat hemophilia.
@en
P2093
Elena Santagostino
Maria Elisa Mancuso
P304
P356
10.1182/BLOOD-2012-01-394411
P407
P577
2012-03-12T00:00:00Z